All In Biotech

Drug Trial Radar · NCT06712407

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO® (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO® 16 mg Once Daily Treatment in Real-world Clinical Practice

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 17, 2024

Primary completion

Mar 2027

Study completion Feb 2028

Sponsor

Lead sponsor
Asahi Kasei Therapeutics, ABIndustry
Sponsor type
Industry
Collaborators
Worldwide Clinical Trials
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will * take part in this study for about 19 months * Have urine tests done * Have blood samples taken * Have physical examinations done

Conditions

  • IgA Nephropathy

Interventions

  • TARPEYO®Drug

    6-months of TARPEYO® 16 mg QD then 9-month Treatment Period with TARPEYO® 8 mg QD and TARPEYO®4 mg QD for 2 weeks for tapering.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ratio of Urine Protein to Creatine Ratio (UPCR) at 6 months compared to BaselineTime frame: 6 months

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • Univ of Alabama/Birmingham

    Birmingham, Alabama

  • Arizona Kidney Disease & Hypertension Centers (AKDHC)

    Glendale, Arizona

  • The Medical Research Group, Inc.

    Fresno, California

  • UCI Health-UCI Medical Center

    Orange, California

  • Loma Linda University

    San Bernardino, California

  • UCSF Health-UCSF Medical Center-Parnassus - Nephrology and Hypertension Faculty Practice

    San Francisco, California

  • Stanford University

    Stanford, California

  • University of Colorado Hospital (UCH) - Kidney Disease and Hypertension Clinic - Anschutz Medical Campus Location

    Aurora, Colorado

  • Yale University Nephrology Clinical Trials Program

    New Haven, Connecticut

  • Florida Kidney Physicians

    Boca Raton, Florida

  • Central Florida Kidney Specialists

    Orlando, Florida

  • Southeastern Clinical Research Institute, LLC

    Augusta, Georgia

  • Cobb Nephrology Hypertension Associates, PC

    Austell, Georgia

  • Georgia Nephrology

    Lawrenceville, Georgia

  • University of Louisville

    Louisville, Kentucky

  • Ochsner Health, New Orleans

    New Orleans, Louisiana

  • University of Maryland Division of Nephrology

    Baltimore, Maryland

  • Boston Medical Center; Boston University Chobanian & Avedisian School of Medicine

    Boston, Massachusetts

  • University of Minnesota Health Fairview

    Minneapolis, Minnesota

  • Washington University in St. Louis

    St Louis, Missouri

  • University of New Mexico

    Albuquerque, New Mexico

  • Renal Medical Associates

    Albuquerque, New Mexico

  • New York Nephrology Vasculitis and Glomerular Center

    Clifton Park, New York

  • Chinatown Kidney Care, PLLC

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • North Carolina Nephrology, P.A

    Raleigh, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic

    Portland, Oregon

  • University of Pennsylvania Philadelphia

    Philadelphia, Pennsylvania

  • Dallas Renal Group

    Dallas, Texas

  • MedResearch Inc

    El Paso, Texas

  • The University of Texas Medical Branch UTMB

    Galveston, Texas

  • Memorial Hermann Houston

    Houston, Texas

  • Prolato Clinical Research Center

    Houston, Texas

  • The Kidney Institute/Houston

    Houston, Texas

  • Dallas Nephrology Associates McKinney

    McKinney, Texas

  • Permian Basin Kidney Center

    Odessa, Texas

  • Advanced Renal Care Institute

    Mayagüez, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.